| |
No-response group
|
Response group
|
P-value
|
|---|
|
Recipient sex, male
|
8/11
|
25/50
|
.171
|
|
Recipient age
|
43.6 ± 15.4
|
47.1 ± 11.7
|
.389
|
|
Donor sex, male
|
5/11
|
27/48
|
.517
|
|
Donor age
|
37.1 ± 9.0
|
37.1 ± 12.3
|
.994
|
|
Hematologic malignancy
| | |
.976
|
|
AML
|
3
|
14
| |
|
ALL
|
4
|
16
| |
|
CML
|
0
|
1
| |
|
NHL
|
0
|
2
| |
|
MDS
|
4
|
17
| |
|
Donor type
| | |
.167
|
|
Unrelated
|
3
|
25
| |
|
Sibling
|
5
|
20
| |
|
FMT
|
3
|
5
| |
|
HLA
| | |
.717
|
|
full-match
|
7
|
36
| |
|
mismatch
|
4
|
14
| |
|
Stem cell source
| | |
1.000
|
|
PB
|
10
|
41
| |
|
BM
|
1
|
7
| |
|
Cord
|
0
|
2
| |
|
Time from HSCT to BOS diagnosis, days
|
407.0 (272.0–1533.0)
|
466.0 (274.3–833.3)
|
.910
|
|
Acute GVHD
|
8/11
|
31/50
|
.731
|
|
Chronic GVHD (except lung)
|
|
Skin
|
6/11
|
25/50
|
0.785
|
|
Oral
|
7/11
|
35/50
|
0.726
|
|
Eyes
|
9/11
|
27/50
|
0.106
|
|
Liver
|
2/11
|
8/50
|
1.000
|
|
Joint
|
0/11
|
3/50
|
1.000
|
|
Maximal score of chronic GVHD (except lung)a
|
1 (1–2)
|
1 (1–2)
|
0.227
|
|
Systemic steroid
|
8/11
|
25/50
|
.171
|
|
Steroid dose, mg (equivalent dose of prednisolone)
|
12.5 (4.4–16.3)
|
2.5 (0.0–15.0)
|
.151
|
|
Tacrolimus
|
3/11
|
15/50
|
1.000
|
|
Cyclosporin
|
1/11
|
8/50
|
.683
|
|
Mycophenolate mofetil
|
5/11
|
13/50
|
.275
|
|
total CAT score, enroll
|
10.5 (6.8–16.0)
|
16.0 (10.0–20.0)
|
.083
|
-
aEach organ was scored as 0, 1, 2 or 3 based on the degree of functional impairment. Data represent the mean ± SD, median (IQR) or n. AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, CML chronic myelogenous leukemia, NHL non-Hodgkin lymphoma, MDS myelodysplastic syndrome, FMT familial-mismatched/haploidentical transplantation, HLA human leukocyte antigen, PB peripheral blood, BM bone marrow, HSCT hematopoietic stem cell transplantation, BOS bronchiolitis obliterans syndrome, GVHD graft-versus-host disease, CAT COPD assessment test
